Congestive Heart Failure Treatment Market, 2012-2023

January 2018 | 189 pages | ID: CAB2647AF42EN
Precision Business Insights (PBI)

Abstracts

Congestive Heart Failure Treatment market: Congestive heart failure is a chronic and progressive condition that affects the pumping capacity of heart muscles and also referred as “heart failure”. Congestive heart failure can refer to the stage in which fluid builds up around the heart and causes it to pump inefficiently. Ventricles pump blood to your body’s organs and tissues, and the atria receive blood from your body as it circulates back from the rest of your body. Congestive heart failure develops when ventricles unable to pump sufficient volume of blood to the body. Eventually, blood and other fluids can back up inside your lungs, liver, abdomen, and lower body. There are two types of congestive heart failure, they are systolic heart failure and diastolic heart failure.

Global Congestive Heart Failure Treatment Market

Increase in prevalence of cardiovascular diseases across regions is one the major factors expected to drive the revenue growth of congestive heart failure treatment globally. Lifestyle related factors are expected to add to growing disease incidence of CVDs. In addition growing number of obese patients are expected to bolster the congestive heart failure treatment market. ast track approvals of drugs in developed countries will propel sales revenues for the companies. Huge treatment demand for congestive heart failure is expected to boost the treatment market developing. However, the availability of the generic drugs and lack of end stage pipeline drugs and therapies for congestive heart failure treatment is about to hinder the market.

Congestive Heart Failure Treatment market is segmented on the basis of the drug class, route of administration, and distribution channel

Based on drug class, congestive heart failure treatment market is segmented as

• Beta Blockers
• ACE Inhibitors
• Angiotensin Receptor Blockers
• Diuretics
• Inotropic Agents
• Aldosterone Antagonist
• Calcium Channel Blockers
• Others

Based on route of administration, congestive heart failure treatment market is segmented as

• Oral
• Intravenous

Based on distribution channel, congestive heart failure treatment market is segmented as

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Congestive heart failure treatment market is expected to show significant growth in demand over the forecast period owing to rising incidences of cardiovascular diseases. Congestive heart failure is one of the most common medical conditions that is responsible for the death of people globally. According to WHO, around 6.5 million of people are diagnosed with congestive heart failure every year and around 2% of global population are hospitalized due to congestive heart failure. In July, 2015, Novartis launched novel combination drug Entresto (LCZ-696) a novel branded CHF drug. The prescription of mineralocorticoid receptor antagonists (MRAs), such as spironolactone, due to their efficiency in heart failure treatment is expected to increase the Congestive heart failure (CHF) treatment markets during the forecast period. Many generic manufacturers foray into the congestive heart failure treatment market due to patent expirations of CHF innovators drugs. The presence generics expected to hinder the market revenue and may hamper the uptake of new and expected novel drugs.

Geographically congestive heart failure treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America and European markets are significantly having high growth potential for congestive heart failure treatment due to the increase in incidences of heart failures in these regions. According to American Heart Association, Heart Disease and Stroke Statistics 2017, congestive heart failure occupies 8.5% of heart diseases in US. merging markets like Asia Pacific and Latin America are set to witness significant growth in this industry due to change in demographics, healthcare reforms, healthcare expenditure, and an increase in treatment for congestive heart failure conditions.

Some of the players in the global congestive heart failure (CHF) treatment market are AstraZeneca plc. (UK), Bristol-Myers Squibb Co. (U.S), GlaxoSmithKline plc (GSK) (UK), Merck & Co. Inc. (U.S), Mylan Inc. (U.S), Novartis AG (Switzerland), Pfizer Inc. (U.S), Sanofi (France), and Valeant Pharmaceuticals International Inc. (Canada)

In July 2015, U.S. Food and Drug Administration (FDA) approved Novartis, Entresto (sacubitril/valsartan) tablets, previously known as LCZ696, to treat heart failure patients with reduced ejection fraction

In April 2015, Amgen received U.S. FDA approval for its Corlanor (ivabradine) to treat of heart failure conditions

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL CONGESTIVE HEART FAILURE TREATMENT MARKET INTRODUCTION

2.1. Global Congestive Heart Failure Treatment Market – Taxonomy
2.2. Global Congestive Heart Failure Treatment Market –Definitions
  2.2.1. Drug Class
  2.2.2. Route of Administration

3. GLOBAL CONGESTIVE HEART FAILURE TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Congestive Heart Failure Treatment Market Dynamic Factors - Impact Analysis

4. GLOBAL CONGESTIVE HEART FAILURE TREATMENT MARKET ANALYSIS, 2012 – 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis

5. GLOBAL CONGESTIVE HEART FAILURE TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

5.1. Beta Blockers
  5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. ACE Inhibitors
  5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis
5.3. Angiotensin Receptor Blockers
  5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.3.3. Market Opportunity Analysis
5.4. Diuretics
  5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.4.3. Market Opportunity Analysis
5.5. Inotropic Agents
  5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.5.3. Market Opportunity Analysis
5.6. Aldosterone Antagonist
  5.6.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.6.3. Market Opportunity Analysis
5.7. Calcium Channel Blockers
  5.7.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.7.3. Market Opportunity Analysis
5.8. Others
  5.8.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.8.3. Market Opportunity Analysis

6. GLOBAL CONGESTIVE HEART FAILURE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

6.1. Oral
  6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. parenteral
  6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis

7. GLOBAL CONGESTIVE HEART FAILURE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

7.1. Hospital Pharmacies
  7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
  7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
  7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL CONGESTIVE HEART FAILURE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

8.1. North America
  8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Congestive Heart Failure Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA CONGESTIVE HEART FAILURE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

9.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.1.1. Beta Blockers
  9.1.2. ACE Inhibitors
  9.1.3. Angiotensin Receptor Blockers
  9.1.4. Diuretics
  9.1.5. Inotropic Agents
  9.1.6. Aldosterone Antagonist
  9.1.7. Calcium Channel Blockers
  9.1.8. Others
9.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.2.1. Oral
  9.2.2. Parenteral
9.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  9.3.1. Hospital Pharmacies
  9.3.2. Retail Pharmacies
  9.3.3. Online Pharmacies
9.4. Country Analysis 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  9.4.1. U.S.
  9.4.2. Canada
9.5. North America Congestive Heart Failure Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
9.6. North America Congestive Heart Failure Treatment Market Dynamics – Trends

10. EUROPE CONGESTIVE HEART FAILURE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

10.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.1.1. Beta Blockers
  10.1.2. ACE Inhibitors
  10.1.3. Angiotensin Receptor Blockers
  10.1.4. Diuretics
  10.1.5. Inotropic Agents
  10.1.6. Aldosterone Antagonist
  10.1.7. Calcium Channel Blockers
  10.1.8. Others
10.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.2.1. Oral
  10.2.2. Parenteral
10.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  10.3.1. Hospital Pharmacies
  10.3.2. Retail Pharmacies
  10.3.3. Online Pharmacies
10.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  10.4.1. Germany
  10.4.2. UK
  10.4.3. France
  10.4.4. Spain
  10.4.5. Italy
  10.4.6. Russia
  10.4.7. Poland
  10.4.8. Rest of Europe
10.5. Europe Congestive Heart Failure Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
10.6. Europe Congestive Heart Failure Treatment Market Dynamics – Trends

11. ASIA-PACIFIC CONGESTIVE HEART FAILURE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

11.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.1.1. Beta Blockers
  11.1.2. ACE Inhibitors
  11.1.3. Angiotensin Receptor Blockers
  11.1.4. Diuretics
  11.1.5. Inotropic Agents
  11.1.6. Aldosterone Antagonist
  11.1.7. Calcium Channel Blockers
  11.1.8. Others
11.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.2.1. Oral
  11.2.2. Parenteral
11.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  11.3.1. Hospital Pharmacies
  11.3.2. Retail Pharmacies
  11.3.3. Online Pharmacies
11.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  11.4.1. Japan
  11.4.2. China
  11.4.3. India
  11.4.4. ASEAN
  11.4.5. Australia & New Zealand
  11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Congestive Heart Failure Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
11.6. Asia-Pacific Congestive Heart Failure Treatment Market Dynamics – Trends

12. LATIN AMERICA CONGESTIVE HEART FAILURE TREATMENT MARKET ANALYSIS, 2012 - 2012 - 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

12.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.1.1. Beta Blockers
  12.1.2. ACE Inhibitors
  12.1.3. Angiotensin Receptor Blockers
  12.1.4. Diuretics
  12.1.5. Inotropic Agents
  12.1.6. Aldosterone Antagonist
  12.1.7. Calcium Channel Blockers
  12.1.8. Others
12.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.2.1. Oral
  12.2.2. Parenteral
12.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  12.3.1. Hospital Pharmacies
  12.3.2. Retail Pharmacies
  12.3.3. Online Pharmacies
12.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  12.4.1. Brazil
  12.4.2. Mexico
  12.4.3. Argentina
  12.4.4. Venezuela
  12.4.5. Rest of Latin America
12.5. Latin America Congestive Heart Failure Treatment Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
12.6. Latin America Congestive Heart Failure Treatment Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA CONGESTIVE HEART FAILURE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023 (REVENUE, USD MN)

13.1. Drug Class Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.1.1. Beta Blockers
  13.1.2. ACE Inhibitors
  13.1.3. Angiotensin Receptor Blockers
  13.1.4. Diuretics
  13.1.5. Inotropic Agents
  13.1.6. Aldosterone Antagonist
  13.1.7. Calcium Channel Blockers
  13.1.8. Others
13.2. Route of Administration Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.2.1. Oral
  13.2.2. Parenteral
13.3. Distribution Channel Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
  13.3.1. Hospital Pharmacies
  13.3.2. Retail Pharmacies
  13.3.3. Online Pharmacies
13.4. Country Analysis 2012 - 2016 and Forecast 2017 – 2023 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
  13.4.1. Gulf Cooperation Council (GCC) Countries
  13.4.2. Israel
  13.4.3. South Africa
  13.4.4. Rest of MEA
13.5. MEA Congestive Heart Failure Treatment Market - Opportunity Analysis Index, By Drug Class, By Distribution Channel, By Route of Administration, and Country, 2017 – 2023
13.6. MEA Congestive Heart Failure Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. AstraZeneca plc. (UK)
  14.2.2. Bristol-Myers Squibb Co. (U.S)
  14.2.3. GlaxoSmithKline plc (GSK) (UK)
  14.2.4. Merck & Co. Inc. (U.S)
  14.2.5. Mylan Inc. (U.S)
  14.2.6. Novartis AG (Switzerland)
  14.2.7. Pfizer Inc. (U.S)
  14.2.8. Sanofi (France)
  14.2.9. Valeant Pharmaceuticals International Inc. (Canada)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS